The fight for ItalianGP pole kicks off in five minutes. Follow all the action as it happens here: F1
16:41Yep, they all come out together apart from both Ferraris, Red Bulls and Tsunoda. The frontrunners look confident of their Q3 spots, while Tsunoda has a back of the grid penalty to serve so he's opting for an early bath.Now it all goes quiet ahead of the final Q2 runs. This could be a case of who blinks first to grab a tow for the last laps.All Q2 drivers apart from Tsunoda have set a lap time, so in danger of dropping out are: Bottas, de Vries, Zhou, Ricciardo and Tsunoda.
So, work to do for both Haas and both Aston Martin drivers, while it looked to be a messy lap for Bottas as he is half a second off team-mate Zhou.Verstappen goes back to the top with a 1m20.922s which is 0.358s quicker than anyone else so far.Norris has a lap time deleted but it won't mean much as it wasn't his fastest time in Q1. All drivers have set a lap time now and in the drop zone with six minutes to go are: Magnussen, Bottas, Stroll, Schumacher and Vettel.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Live: Follow F1 Italian GP practice as it happens | Live text | Motorsport.comFollow live Formula 1 updates on all of the Saturday action at Monza ahead of the Italian Grand Prix.
Read more »
Live: F1 Italian GP commentary and updates - FP3 & Qualifying | Live text | Autosport.comIt has been a busy morning at Monza so far... Catch up with the F1 action before final practice for the ItalianGP begins ⬇️
Read more »
Live: Follow F1 Italian GP practice as it happens | Live text | Motorsport.comIt's time for the F1 track action to kick off at Monza. Follow first ItalianGP practice live with us:
Read more »
Live: F1 Italian GP commentary and updates - FP1 & FP2 | Live text | Autosport.comF1 practice for the ItalianGP is just around the corner 🇮🇹 Follow along with Autosport Live for all of the updates as they happen ⬇️
Read more »
Pulmonary function and chest computed tomography abnormalities 6–12 months after recovery from COVID-19: a systematic review and meta-analysis - Respiratory ResearchBackground Some coronavirus disease 2019 (COVID-19) survivors experience prolonged and varying symptoms, a condition termed post-acute COVID-19 syndrome (PACS). However, the prevalence of chronic pulmonary sequelae of PACS during long-term follow-up remains unclear. Several studies have examined this issue and reported heterogeneous results. Methods We conducted a systematic review and meta-analysis using a random-effects model to estimate the pooled prevalence of the pulmonary sequelae of COVID-19, as demonstrated by pulmonary function testing (PFT) and chest computed tomography (CT) performed at least 6 months after initial infection. PubMed, Embase, and Cochrane Library databases were searched from January 1, 2020 to December 31, 2021 to identify related studies. We investigated whether the prevalence of pulmonary sequelae decreased over time and attempted to identify the factors associated with their development by performing multiple subgroup and meta-regression analyses. Results Of the 18,062 studies identified, 30 met our eligibility criteria. Among these studies, 25 and 22 had follow-up PFT and chest CT data, respectively. The follow-up durations were approximately 6 and 12 months in 18 and 12 studies, respectively. Impaired diffusion capacity was the most common abnormality on PFT (pooled prevalence 35%, 95% confidence interval [CI] 30–41%) with a prevalence of 39% (95% CI 34–45%) and 31% (95% CI 21–40%) in the 6-month and 12-month follow-up studies, respectively (P = 0.115). Restrictive pulmonary dysfunction evident as reduced forced vital capacity was less frequent (pooled prevalence 8%, 95% CI 6–11%); however, its prevalence was lower in the 12-month follow-up studies than in the 6-month follow-up studies (5% [95% CI 3–7%] vs. 13% [95% CI 8–19%], P = 0.006). On follow-up chest CT, the pooled prevalence of persistent ground-glass opacities and pulmonary fibrosis was 34% (95% CI 24–44%) and 32% (95% CI 23–40%), respectively, and the prevalence did not decr
Read more »